Clinical Trials Logo

Clinical Trial Summary

This is a Phase 1, open-label, parallel-group, single-dose study of lofexidine in 6 adult subjects with mild hepatic impairment (Child Pugh score of 5 6), 6 adult subjects with moderate hepatic impairment (Child Pugh score 7 9), 6 adult subjects with severe hepatic impairment (Child Pugh score 10 15), and 6 control subjects with normal hepatic function with mean age, body mass index (BMI), and gender distribution targeted to be similar to the impaired hepatic function cohorts.


Clinical Trial Description

This is a Phase 1, open-label, parallel-group, single-dose study of lofexidine in 6 adult subjects with mild hepatic impairment (Child Pugh score of 5 6), 6 adult subjects with moderate hepatic impairment (Child Pugh score 7 9), 6 adult subjects with severe hepatic impairment (Child Pugh score 10 15), and 6 control subjects with normal hepatic function with mean age, body mass index (BMI), and gender distribution targeted to be similar to the impaired hepatic function cohorts. Subjects will be confined to an inpatient facility from the evening before dosing to 144 hours after dosing.

Subjects who successfully complete screening will report to the inpatient facility at an appropriate time the evening before study drug administration (Day 1) to ensure a minimum 10 hour fast. The next morning (Day 1) while still fasting, subjects will receive a single, oral dose of 400 µg lofexidine HCl (two 200 µg tablets). Blood samples will be collected for pharmacokinetic (PK) analysis at multiple time points over the next 144 hours (Day 7). Pooled urine samples will be collected at 0 3 hours, 3 6 hours, 6 12 hours, 12 24 hours, 24 48 hours, 48 96 hours, 96 120 hours and 120 144 hours post-dose. Safety will be assessed by recording adverse events (AEs), measuring vital signs (blood pressure and pulse rate) and clinical laboratory tests (chemistry, hematology, and urinalysis), recording 12 lead safety and Holter electrocardiograms (ECGs), and performing physical exams. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02318836
Study type Interventional
Source US WorldMeds LLC
Contact
Status Completed
Phase Phase 1
Start date June 2014
Completion date October 2014

See also
  Status Clinical Trial Phase
Recruiting NCT03791190 - RCA for CRRT in Liver Failure and High Risk Bleeding Patients N/A
Recruiting NCT05989958 - The Safety and Tolerability Study of HepaCure in Chinese Subjects With Acute-On-Chronic Liver Failure Phase 1
Completed NCT02557724 - Mobilization of Mesenchymal Stem Cells During Liver Transplantation
Recruiting NCT01698723 - A Trial of Ribavirin in Patients With ACLF Due to Hepatitis E Virus Phase 2
Completed NCT01404793 - SPME For Metabolomics And Concomitant Measurements Of Rocuronium Bromide Levels In Liver Transplantation N/A
Completed NCT01425385 - Autoregulation Assessment During Liver Transplantation N/A
Completed NCT00808691 - Microcirculation and Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit N/A
Completed NCT03864497 - Myocardial Perfusion Imaging in Liver Transplantation Candidates
Completed NCT00287235 - Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS) N/A
Completed NCT03650920 - Hepatitis C Virus (HCV) Positive Liver Grafts in HCV Negative Recipients N/A
Recruiting NCT05517668 - Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose Phase 2
Recruiting NCT05726032 - Empagliflozin in Patients With Cirrhosis and Ascites Phase 2
Recruiting NCT04548596 - NOninVasive Intracranial prEssure From Transcranial doppLer Ultrasound Development of a Comprehensive Database of Multimodality Monitoring Signals for Brain-Injured Patients
Recruiting NCT02331745 - RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure Phase 4
Not yet recruiting NCT01961440 - Prognosis Scoring System for Acute-on-Chronic Liver Failure N/A
Active, not recruiting NCT01221454 - Allogenic Bone Marrow Stem Cell Transplantation in Liver Failure Phase 2
Completed NCT00772148 - Pharmacokinetics of LCP-Tacroâ„¢ Once Daily and Prograf® Twice A Day in Adult De Novo Liver Transplant Patients Phase 2
Completed NCT05592106 - Gd-EOB-DTPA-enhanced T1 Map for Predicting Postoperative Liver Failure
Not yet recruiting NCT06014320 - Alterations in Coagulation Factor Levels in Patients With End Stage Liver Disease
Recruiting NCT04221672 - The Effect of Terlipressin on Recovery of Liver Function After Hepatectomy Phase 3